TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06971939: Phase 4 Study: Long-term Safety and Efficacy of NT-501 in MacTel Type 2, Including Sham Procedure Participants

Sponsor: Neurotech Pharmaceuticals · Phase: PHASE4 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 234 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$2,045,120

Rescue Site Savings

+$1,354,560

Unlock Full NCT06971939 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06971939 Rescue Dossier →